Agomab
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Agomab - overview
Established
2017
Location
Antwerpen, -, Belgium
Primary Industry
Biotechnology
About
Based in Belgium, AgomAb Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for restoring organ function and treating fibrotic diseases. AgomAb Therapeutics NV, founded in 2017 in Ghent, Belgium, specializes in creating therapies for fibrotic diseases. In February 2026, AgomAb Therapeutics NV raised USD 200 million in an IPO, selling 12. 5 million shares at USD 16 per share per share at Nasdaq, under the ticker "AGMB".
As of March 2026, Tim Knotnerus serves as Chief Executive Officer. AgomAb Therapeutics NV develops innovative therapies specifically targeting fibrotic diseases. Its lead product, AGMB-129, is an oral small molecule inhibitor aimed at treating Fibrostenosing Crohn’s Disease (FSCD), currently undergoing clinical testing in the STENOVA1 Phase 2a trial across the USA, Canada, and Europe. While specific revenue figures are not disclosed, AgomAb's revenue structure is likely based on partnerships and clinical trial outcomes in the biopharmaceutical sector, involving agreements for clinical trial participation, milestone payments, and potential royalties upon successful commercialization.
The company will use the February 2026 funding for research and development purposes.
Current Investors
Omnes Capital, Pontifax Venture Capital, Boehringer Ingelheim Venture
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.agomab.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Agomab - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.